Anavex Life Sciences Corporation (AVXL) Quote

What’s the title?

The actual presentation trial is very very impressive.

If you disagree, then maybe you should short AVXL even more than you already have shorted AVXL.

GOD bless,

well said, really well said

In other words, the presentation title doesn't impress and actually will most likely not present anything new.

He is making a presentation directly about Anavex's blarcamesine Phase 2b/3 trial results.

Good luck and GOD bless,

What’s the headline of his presentation? Because he’s not talking specifically about Anavex

Cassava Sciences: Turning The Corner Into A Brick Wall - By Lane Simonian

https://seekingalpha.com/article/4706021-cassava-sciences-turning-the-corner-into-a-brick-wall?mailingid=36173368&messageid=must_reads&serial=36173368.924982&source=email_must_reads&utm_campaign=Must%2BReads%2B-%2BProduct%2Bteam%2Btest%2B-%2BNo%2Btest%2Bversion%2B2024-07-24&utm_content=seeking_alpha&utm_medium=email&utm_source=seeking_alpha&utm_term=must_reads

I think you pur in too much thought in this post. What kind of thought who knows

Here goes my technical analysis: the closing price of $6.48 represents the lower channel of the band that extended through to $6.73. $6.73 represents the resistance zone, as this price has been tested, retested, and retreated. Bollinger bands and stochastic modeling indicate the price could go higher, but it certainly could go lower as well. The key to watch for is if the color is green, the price is higher, which then means it could go lower or remain unchanged, as traders generally want to make money. Look for the stock to go up or down, but it might also remain unchanged if buyers lack conviction. It’s too hard to call right now, so I’ll get back to you tomorrow at 4:30 to let you know what already happened.

Why your "study group" is empty.

You might be better off counting the waves in the ocean.

Suggestion: Go to the beach and count the waves lapping the shoreline. This analysis is pure, unadulterated crap.

Looking at EW...
Like you said ,counting waves can be a little tricky. You can see 5 waves up, but also it could extend to 7 waves. I've even counted 9 waves in a finished pattern at times.
Sometimes it helps when I go back to the bottom and start over. I can clearly see the 1st upwave, from 3.25/3.40 bottom to finish peak around 4.50/4.60. As Wave 1
Wave 2 pulls back and holds support at 3.50/3.65/3.73.
Then we get the latest surging upwave that peaked at 6.80. This is the more difficult wave to analyze because depending on how you count it, could be a wave 3,4,and 5 finished.Or... it could be just one wave 3, you know ,like counting 1 of 5 of 3, 2 of 5 of 3, etc. The pullback around 6.40 is looking zig zaggy like a Wave 4.... so that's why I'm thinking the surge to 6.80 was only a Wave 3 , now sideways zig zag is wave 4, and we could anticipate wave 5 to target 7.60-8.40 area as a finished pattern.

I know it is the LATEST information
and in context is lowest in 6+ reports except
for the last

BUT….to think the increase correlates as you posited with today’s/recent SP is very much a stretch.
Any takers the next report (representative of today’s positioning) is fewer shorts?

“Why look for conspiracy when stupidity can explain so much.”
Goethe

Even the BMW should sound loud in the Chesapeake Tunnel/Bridge. Kittyhawk and home Friday.

What will Monday think of AAIC and AVXL?

Shorty trying to keep a cap on the price maybe.🤔

You mean Misleading finally found a needle in the haystack. Is it the right needle or another nothingburger?

Piano player Pauline Stevens--video a bit dated yet so meaningful--why no followup coverage--???? https://www.heraldsun.com.au/news/national/steve-macfarlane-explains-the-alzheimers-worldfirst-drug-trial-at-caulfield-hospital/video/03fe27ae89bdce4912cabf865a99ed80

YES!!! I am expecting new--needle moving info from this presentation!!!

MRI brain volume (atrophy) etc.

Good luck and GOD bless,

https://www.nasdaqtrader.com/Trader.aspx?id=ShortInterest

"The oral session is scheduled for 4:30"--george--are you expecting-anything new--needle moving info from this Presentation ????

Nasdaq 17,342.41 -654.94 (-3.64%)

AVXL held up pretty well considering the entire markets were deep in the red.

short shares are up and our SP is up as well humm.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

Where do you get latest short interest? Nasdaq only shows 6/28/2024. Thanks.

Short Report just out: 07/15/2024 18,440,980

07/15/2024 18,440,980 3.45 802,783 22.97
06/28/2024 17,825,737 (14.89) 1,692,163 10.53
06/14/2024 20,944,467 (4.00) 1,071,745 19.54
05/31/2024 21,816,277 (0.20) 1,033,741 21.10
05/15/2024 21,860,442 2.68 1,029,913 21.23

https://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Right! It's only under valued by $75.00 per share or so. Lol..

The oral session is scheduled for 4:30 PM EDT on Sunday 28 July 2024.

The shorts have to cover on Friday 26 July 2024 if the need to cover before the AAIC presentation.

Good luck and GOD bless,

super strong today.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

Holding up here...1 minute chart

https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=Stock&symb=avxl&x=23&y=13&time=1&startdate=1%2F4%2F1999&enddate=4%2F12%2F2018&freq=9&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=1&maval=55550&uf=8&lf=2&lf2=8&lf3=4&type=4&style=350&size=4&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=11

Looks like the Standoff at the OK Coral

I thought the volume would have been less, but this certainly shows that outside interests don't want to risk seeing $7 broken! With the NASDAQ down 3.50% and the short interest coming out after 4pm,

I think the stock itself has held up pretty darn well....still 40 minutes to go; I am flat footed right now.

Blarcamesine's safety, efficacy and ease of use likely raises concerns for BP's mabs which has seen a sales drop. And then there's the EMA that's waiting on a better alternative... such as a safe effective oral pill that reduces brain shrinkage. hmm

Which session/time is that, George?

This coming Sunday 28 July 2024 Dr. Marwan N Sabbagh, MD will be make an oral presentation at the 2024 AAIC Meeting concerning the results from the Phase 2b/3 Alzheimer's trial using blarcamesine.

That means that Friday 26 July 2026 will be the last time for the shorts to cover before the AAIC Meeting!!!

Good luck and GOD bless,

Expect the AVXL share price to close at or near the high of the day on increasing buying volume near the close of trading today.

Good luck and GOD bless,

Some hedge firms/MM must be worried about the growth side of Anavex's SP, such that, they brought Anshu2 back after 2+ months away (and probably from other assignments under another name(s)).

Alzheimer AAIC conference; Session listings:

https://alz.org/media/Documents/scientific-conferences/AAIC-2024-Program-Alzheimers-Association.pdf

see below as evidence supporting Xenalives post:

Two of the most significant biomarkers found in Alzheimer’s are decreased glucose uptake and the accumulation of amyloid plaques in the brain. PET scans use different radioactive drugs, called radiotracers, to measure these biomarkers within the brain tissue of patients with cognitive impairment. FDG-PET is one of the most commonly used imaging techniques to diagnose Alzheimer’s. However, in recent years, several other radiotracers, such as florbetapir, have been developed to detect the deposition of amyloid plaques.

Recently, the effectiveness of amyloid imaging as a strategy for monitoring dementia symptoms has been called into question. While the presence of amyloid plaques in the brain is considered as being characteristic of Alzheimer’s, some studies have shown that large amounts of amyloid plaques were present in healthy, non-demented individuals. Conversely, recent clinical trials have shown that the intended removal of amyloid from the brains of patients with Alzheimer’s disease led to no change in, or even worsened, cognitive performance.

IMO, there is a massive pile of evidence which clearly contradicts FDA claims of any certain causal links . Why-how the FDA have continued w/this is baffling.

https://www.pennmedicine.org/news/news-releases/2019/august/measuring-brains-amyloid-buildup-less-effective-alzehimers-disease-compared-imaging-methods#:~:text=While%20the%20presence%20of%20amyloid,

The rest of the market appears "soft", but we're up on nearly 800,000 shares traded!

Thanks, Kevin and the link addresses this, too!

Thanks for your reply, Xena!

S1R is a potential therapeutic target for traumatic brain injury.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515188/

Thats speculation.
FDA does not encourage (in fact, strongly discourages) NDA filing until they see some semblance of a chance.
EMA should be similar. They certainly saw AVXL data --- whether they "encouraged" or merely said "the approval depends on careful review (i.e., data doesn't look insufficient/terrible, so its a matter of review)" ... we'll never know.

Plaque attack drugs will not work long term because plaque is a symptom, not a cause.

Fromm your link:

"About Buntanetap

Buntanetap (formerly known as Posiphen or ANVS401) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This improves synaptic transmission, axonal transport, and reduces neuroinflammation. Dysregulation of these pathways has been shown to cause nerve cell degeneration and ultimately nerve cell death. By targeting these pathways, buntanetap has the potential to reverse neurodegeneration in Alzheimer’s, Parkinson’s, and other neurodegenerative diseases, thereby aiming to restore brain function and improve the quality of life for patients."

it's tonight after the close

My guess is 15 million short shares down by another 2 million on this next report.

I saw a news item from one of our competitors this morning about Traumatic Brain Injury for ALZ and it had a very short term positive response but is now fading....certainly something I was not aware of....any of you aware of this and how important it might be?

https://irpages2.eqs.com/websites/annovis/English/431010/us-press-release.html?airportNewsID=f839ba7e-3d56-48da-bc0f-81caf92082d1

feel like we about to liftoff.JUST HOLD ON TIGHT LOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOONGS

Looking at the pounding the general market is having right now might have some impact on $AVXL for a short while, but I feel it should be pretty light and on lesser volume....somewhere around the previous print low around $6.37 plus or minus....with a very robust rally then taking out the overhead prior resistance in January and February (and recently) around $6.90....the push should be substantial without relying on my crystal ball....or is it an eight ball? Momentum is not yet destroyed therefore anticipating further progress seems reasonable.

PS Don't forget the hedge funds and mm's will try to stop any advance past $7 which I think is not warranted

You must be kidding.....

1. Are there any STUDIES that show the connection of brain shrinkage to AD functional benefit? (Not anecdotal data, but serious studies). I doubt it.
2. Even if these studies exist -- are they for the similar parts of the brains, as AVXL's drug work?


This is basic science...

Brain atrophy is a loss of neurons that occurs in Alzheimer's disease and is a widely accepted biomarker for the disease. In Alzheimer's, brain atrophy is accelerated compared to the atrophy that occurs with age, even in people who are cognitively healthy. Alzheimer's disrupts the processes that are vital to neurons and their networks, including communication, metabolism, and repair. This damage can cause many neurons to stop functioning properly, lose connections with other neurons, and eventually die.

National Institute on Aging
What Happens to the Brain in Alzheimer's Disease?
Jan 19, 2024 — How does Alzheimer's affect the brain? The brain typically shrinks to some deg...

Alzheimer's Association
Brain Atrophy and B Vitamins - Alzheimer's Association
September 22, 2010. Brain atrophy involves the loss of neurons. Some degree of atrophy and...

ScienceDirect.com
Predicting brain atrophy from tau pathology: a summary of ...
Atrophy rates are higher in pre-symptomatic and symptomatic Alzheimer's patients than in h...
The medial temporal lobe (MTL) is the first region of the brain to show atrophy in Alzheimer's disease. Over time, there are four main patterns of atrophy in Alzheimer's disease:
Progressive hippocampal and cortical atrophy: 59% of patients
Progressive hippocampal atrophy only: 19% of patients
Progressive cortical atrophy only: 12% of patients
No atrophy in either region: 10% of patients
Symptoms of brain atrophy can vary depending on which part of the brain is damaged and can range from mild to severe. Some symptoms include:
Aphasia
Difficulty speaking or writing
Inability to understand the meaning of words
Dementia
Hallucinations
Loss of language
Memory problems
Mood and personality changes
Poor judgment
Seizures
This is for informational purposes only. For medical advice or diagnosis, consult a professional. Generative AI is experimental.


You don't have a clue when it comes to the science ... search this thread for the term "autophagy" and read the discussion.

You can also read this article:
https://www.nature.com/articles/s43587-021-00098-4

Maybe egg salad sandwich on rye toast & tomato soup for lunch ....and don't forget to bring some Liquid Plumber for your luncheon guest; surely that would be a welcome gift for her?

You need to follow FDA much more closely and carefully. The SRPT's first drug (Eteplersin) approval process is a good case study (I know it was finally approved, but only because J Woodcock put her foot down). It may have been overly wrong/lenient for Adu approval, but thats extremely rare.